Interim results from the AROAAT2002 study (NCT03946449) demonstrated that ARO-AAT was not only well tolerated but also capable of inhibiting Z-AAT expression, reducing intrahepatic Z-AAT accumulation to allow the clearance of Z-AAT polymers and improving liver fibrosis. Here, SERPINA1 is linked to Hepatic fibrosis.